Inventiva Stock price

Equities

IVA

FR0013233012

Biotechnology & Medical Research

Real-time Euronext Paris 08:40:51 2024-03-28 am EDT 5-day change 1st Jan Change
3.25 EUR -2.99% Intraday chart for Inventiva -7.14% -20.63%
Sales 2023 * 9.44M 10.18M Sales 2024 * 4.07M 4.39M Capitalization 174M 188M
Net income 2023 * -88M -94.9M Net income 2024 * -89M -95.98M EV / Sales 2023 12.1 x
Net Debt 2023 * 19.34M 20.86M Net Debt 2024 * 91.74M 98.94M EV / Sales 2024 * 65.3 x
P/E ratio 2023
-1.69 x
P/E ratio 2024 *
-2.47 x
Employees 117
Yield 2023 *
-
Yield 2024 *
-
Free-Float 98.58%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Inventiva

1 day-1.79%
1 week-6.00%
Current month+1.86%
1 month+2.33%
3 months-21.20%
6 months-15.21%
Current year-19.66%
More quotes
1 week
3.12
Extreme 3.12
3.56
1 month
3.12
Extreme 3.12
4.30
Current year
2.80
Extreme 2.8
4.44
1 year
1.88
Extreme 1.88
4.84
3 years
1.88
Extreme 1.88
13.18
5 years
1.54
Extreme 1.54
16.30
10 years
1.54
Extreme 1.54
16.30
More quotes
Managers TitleAgeSince
Founder 62 11-10-26
Chief Executive Officer 58 11-10-26
Director of Finance/CFO 59 12-07-31
Members of the board TitleAgeSince
Director/Board Member 49 18-05-27
Director/Board Member 59 17-02-13
Director/Board Member 73 17-01-31
More insiders
Date Price Change Volume
24-03-28 3.25 -2.99% 87 283
24-03-27 3.35 -5.77% 77,497
24-03-26 3.555 +3.80% 47,363
24-03-25 3.425 -2.00% 36,957
24-03-22 3.495 -0.14% 30,850

Real-time Euronext Paris, March 28, 2024 at 06:36 am EDT

More quotes
Inventiva is a biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology. The group is developing two drug candidates - lanifibranor and odiparcil - in non-alcoholic steatohepatitis (« NASH ») and mucopolysaccharidosis (« MPS ») respectively, as well as a portfolio of several programs in the preclinical stage. Lanifibranor, is currently in a pivotal Phase III clinical trial « NATiV3 » for the treatment of patients with NASH and Odiparcil is currently in Phase IIa for the treatment of type VI MPS. As part of Inventiva's decision to focus clinical efforts on the development of Lanifibranor, it suspended clinical efforts relating to Odiparcil and is reviewing available options with respect to its potential further development. Meanwhile, Inventiva is in the process of selecting an oncology drug candidate for the Hippo signaling pathway. Furthermore, the company has established a strategic collaboration with AbbVie, which is currently evaluating Cedirogant (ABBV-157) in a Phase IIb clinical trial. This partnership provides for milestone payments to Inventiva as well as royalties on product sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.35 EUR
Average target price
13.93 EUR
Spread / Average Target
+315.92%
Consensus
  1. Stock
  2. Equities
  3. Stock Inventiva - Euronext Paris